HIGHLIGHTS
- who: Yue Zhang and colleagues from the School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China have published the article: Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis, in the Journal: Cardiology Research and Practice of 26/04/2022
- what: The authors aimed to investigate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on blood lipid levels in patients with high and very-high cardiovascular risk. Due to the different standards for high risk . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.